Susquehanna International Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-26,500
| Closed | -$155K | – | 14078 |
|
|
2022
Q4 | $155K | Buy |
26,500
+15,900
| +150% | +$83.6K | ﹤0.01% | 10462 |
|
|
2022
Q3 | $71K | Sell |
10,600
-31,100
| -75% | -$189K | ﹤0.01% | 11987 |
|
|
2022
Q2 | $176K | Buy |
41,700
+26,500
| +174% | +$105K | ﹤0.01% | 10828 |
|
|
2022
Q1 | $51K | Sell |
15,200
-10,600
| -41% | -$33.6K | ﹤0.01% | 12311 |
|
|
2021
Q4 | $81K | Buy |
25,800
+14,000
| +119% | +$46.6K | ﹤0.01% | 12279 |
|
|
2021
Q3 | $39K | Sell |
11,800
-2,900
| -20% | -$10.2K | ﹤0.01% | 12429 |
|
|
2021
Q2 | $62K | Sell |
14,700
-5,200
| -26% | -$22K | ﹤0.01% | 12247 |
|
|
2021
Q1 | $99K | Buy |
+19,900
| New | +$161K | ﹤0.01% | 11871 |
|
|
2020
Q1 | – | Sell |
-22,900
| Closed | -$211K | – | 11119 |
|
|
2019
Q4 | $211K | Buy |
22,900
+2,200
| +11% | +$15.6K | ﹤0.01% | 8677 |
|
|
2019
Q3 | $122K | Sell |
20,700
-20,900
| -50% | -$222K | ﹤0.01% | 9452 |
|
|
2019
Q2 | $499K | Buy |
41,600
+11,300
| +37% | +$122K | ﹤0.01% | 7264 |
|
|
2019
Q1 | $366K | Buy |
30,300
+8,700
| +40% | +$128K | ﹤0.01% | 6864 |
|
|
2018
Q4 | $271K | Sell |
21,600
-1,800
| -8% | -$24.9K | ﹤0.01% | 7187 |
|
|
2018
Q3 | $347K | Buy |
23,400
+7,900
| +51% | +$124K | ﹤0.01% | 7197 |
|
|
2018
Q2 | $261K | Sell |
15,500
-2,400
| -13% | -$46.6K | ﹤0.01% | 8121 |
|
|
2018
Q1 | $410K | Sell |
17,900
-11,700
| -40% | -$260K | ﹤0.01% | 7029 |
|
|
2017
Q4 | $766K | Buy |
29,600
+17,300
| +141% | +$348K | ﹤0.01% | 5773 |
|
|
2017
Q3 | $181K | Sell |
12,300
-100
| -0.8% | -$1.45K | ﹤0.01% | 8090 |
|
|
2017
Q2 | $173K | Sell |
12,400
-32,200
| -72% | -$475K | ﹤0.01% | 8408 |
|
|
2017
Q1 | $761K | Buy |
+44,600
| New | +$535K | ﹤0.01% | 5704 |
|
Susquehanna International Group's CNCE Position: Q1 2023 in Review
Susquehanna International Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 240,190 shares — an estimated $1.4M sold.
Susquehanna International Group first reported a position in CNCE in Q2 2014 and held it in 17 quarters. The position peaked at $1.4M in Q4 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Susquehanna International Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Susquehanna International Group sold 240,190 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $1.4M.
- Susquehanna International Group first reported a position in Concert Pharmaceuticals, Inc. in Q2 2014 and held it in 17 quarters.
- Susquehanna International Group's Concert Pharmaceuticals, Inc. position peaked at $1.4M in Q4 2022.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.